Background:

CD272, also known as B and T lymphocyte attenuator (BTLA), is an Ig superfamily co-inhitory receptor with structural similarity to programmed cell death 1 (PD-1) and CTLA-4. BTLA is expressed on B cells, T cells, macrophages, dendritic cells, NKT cells, and NK cells. Engagement of BTLA by its ligand herpes virus entry mediator (HVEM) is critical for negatively regulating immune response. The absence of BTLA with HVEM inhibitory interactions leads to increased experimental autoimmune encephalomyelitis severity, enhanced rejection of partially mismatched allografts, an increased CD8+ memory T cell population, increased severity of colitis, and reduced effectiveness of T regulatory cells. BTLA plays an important role in the induction of peripheral tolerance of both CD4+ and CD8+ T cells in vivo. Tolerant T cells have significantly higher expression of BTLA compared with effectors and nave T cells. BTLA may cooperate with CTLA-4 and PD-1 to control T cell tolerance and autoimmunity. It was reported that BTLA may regulate T cell function by binding to B7-H4, but further studies are needed to confirm. The existence of three distinct BTLA alleles has been reported.

Alternative names:

B- and T-lymphocyte attenuator,Btla,B- and T-lymphocyte-associated protein,CD272,Btla

Description:

Antibody for flow cytometry

Species reactivity:

Mouse

Host:

Rat

Isotype:

Rat IgG1, κ

Concentration:

0.5 mg/mL

Buffer:

PBS with 0.05% Proclin300

Conjugation:

Unconjugated

Applications:

FCM

Storage:

Store at 2~8°C. Do not freeze.

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com